Eli Lilly and Company (LLY)

NYSE
Currency in USD
812.03
+3.42(+0.42%)
Closed·
Pre Market
802.06-9.97(-1.23%)
·
LLY Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
LLY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
806.35818.56
52 wk Range
677.09972.53
Key Statistics
Edit
Prev. Close
812.03
Open
810.33
Day's Range
806.35-818.56
52 wk Range
677.09-972.53
Volume
2.27M
Average Volume (3m)
4.07M
1-Year Change
-6.37%
Book Value / Share
17.56
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LLY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
951.98
Upside
+17.23%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Eli Lilly and Company News & Analysis

Show more

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Employees
47000

Eli Lilly and Company SWOT Analysis


GLP-1 Market Leade
Eli Lilly's dominance in diabetes and obesity treatments, driven by Mounjaro and Zepbound, propels impressive 32% revenue growth despite recent challenges
Financial Forecast
Explore Eli Lilly's robust 2025 guidance, projecting revenues between $58-61 billion, surpassing consensus estimates and reflecting confidence in growth trajectory
Pipeline Potential
Delve into Eli Lilly's promising pipeline, including oral GLP-1 agonist orforglipron, poised to revolutionize diabetes and obesity treatment markets
Analyst Optimism
Discover why analysts maintain bullish outlook on Eli Lilly, with price targets ranging from $970 to $1,250, reflecting strong growth prospects and market position
Read full SWOT analysis

Eli Lilly and Company Earnings Call Summary for Q1/2025

  • Q1 revenue up 45% YoY to $12.73B, driven by key products; EPS of $3.34 missed $3.46 forecast
  • Stock dropped 8.56% post-earnings; company trades above Fair Value per InvestingPro analysis
  • Gross margin improved to 83.5%; non-GAAP performance margin up 11+ points to 42.6%
  • Full-year revenue guidance reaffirmed; phase 3 data for orforglipron expected by end of 2025
  • CEO highlighted promising Achieve One trial results, increased U.S. manufacturing investments
Last Updated: 02/05/2025, 01:18 am
Read Full Transcript

Compare LLY to Peers and Sector

Metrics to compare
LLY
Peers
Sector
Relationship
P/E Ratio
65.6x18.1x−0.5x
PEG Ratio
0.810.070.00
Price/Book
46.2x2.8x2.6x
Price / LTM Sales
14.9x4.2x3.1x
Upside (Analyst Target)
20.0%207.1%48.3%
Fair Value Upside
Unlock15.5%7.6%Unlock

Analyst Ratings

23 Buy
4 Hold
2 Sell
Ratings:
29 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 951.98
(+17.23% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 12.34%
Dividend Yield
0.74%
Industry Median 1.73%
Annualised payout
6.00
Paid quarterly
5-Years Growth
+15.08%
Growth Streak

Earnings

Latest Release
May 01, 2025
EPS / Forecast
3.34 / 3.46
Revenue / Forecast
12.73B / 12.72B
EPS Revisions
Last 90 days

LLY Income Statement

People Also Watch

132.30
PEP
+1.85%
239.99
GE
-2.25%
363.16
HD
+0.75%
469.27
LMT
+2.77%
318.50
UNH
+2.56%

FAQ

What Is the Eli Lilly (LLY) Stock Price Today?

The Eli Lilly stock price today is 812.03

What Stock Exchange Does Eli Lilly Trade On?

Eli Lilly is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Eli Lilly?

The stock symbol for Eli Lilly is "LLY."

Does Eli Lilly Pay Dividends? What’s The Current Dividend Yield?

The Eli Lilly dividend yield is 0.74%.

What Is the Eli Lilly Market Cap?

As of today, Eli Lilly market cap is 728.99B.

What Is Eli Lilly's Earnings Per Share (TTM)?

The Eli Lilly EPS (TTM) is 12.34.

When Is the Next Eli Lilly Earnings Date?

Eli Lilly will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is LLY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Eli Lilly Stock Split?

Eli Lilly has split 5 times.

How Many Employees Does Eli Lilly Have?

Eli Lilly has 47000 employees.

What is the current trading status of Eli Lilly (LLY)?

As of 12 June 2025, Eli Lilly (LLY) is trading at a price of 812.03, with a previous close of 812.03. The stock has fluctuated within a day range of 806.35 to 818.56, while its 52-week range spans from 677.09 to 972.53.

What Is Eli Lilly (LLY) Price Target According to Analysts?

The average 12-month price target for Eli Lilly is USD951.97519, with a high estimate of USD1190 and a low estimate of USD650. 23 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +17.23% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.